Hermine O, Maciel Th, Moura I
Département d'hématologie, Centre National de référence des mastocytoses et Institut Imagine, Paris Descartes university, Hôpital Necker, 149 Rue de Sèvres, 75015 Paris.
Département d'hématologie, Centre National de référence des mastocytoses et Institut Imagine, Paris Descartes university, Hôpital Necker, 149 Rue de Sèvres, 75015 Paris.
Nephrol Ther. 2017 Jun;13(6S):6S7-6S10. doi: 10.1016/S1769-7255(18)30034-8.
Erythropoietin (EPO) plays an essential role in the regulation of erythropoiesis. Its production is under the control of the Hypoxia Inducible Factor (HIF) protein whose stability varies according to the oxygen level. During chronic renal failure, EPO deficiency is the main cause of anemia, but other factors such as iron deficiency and inflammatory syndrome are also involved. More recently, it is hypothesized that other factors such an excess of GDF-11 production may be also involved. Thus, beside Epo treatment HIF and GDF-11 are potentially new therapeutic targets in anemia of chronic kidney disease.
促红细胞生成素（EPO）在红细胞生成的调节中起着至关重要的作用。其产生受缺氧诱导因子（HIF）蛋白的控制，HIF蛋白的稳定性会根据氧水平而变化。在慢性肾衰竭期间，EPO缺乏是贫血的主要原因，但其他因素如缺铁和炎症综合征也有影响。最近，有人推测其他因素如GDF-11产生过多也可能参与其中。因此，除了Epo治疗外，HIF和GDF-11可能是慢性肾脏病贫血新的治疗靶点。
